MN
Manuel Navas Piper Sandler Latest Price Targets & Analyst Ratings
Main Sector
Financials
Ratings Past Year
37
Avg Return
Past Year
Past Year
6.7%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past 3 Months
Positive
35.7%
Neutral
64.3%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Financials
Healthcare
Financials
Banks - Diversified
Banks - Regional
Healthcare
Biotechnology
| Stock | Rating | Price Target |
Upside Downside |
Ratings 3 Months |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Reiterated
| $22 |
12%
upside
| 1 | +11% |
0
%
| 3 Feb ‘26 29 days ago |
|
|
|
Neutral
Reiterated
| $36 |
13%
upside
| 2 | – |
–
| 2 Feb ‘26 1 month ago |
|
|
|
Neutral
Reiterated
| $24 |
13%
upside
| 2 | – |
–
| 30 Jan ‘26 1 month ago |
|
|
|
Neutral
Maintained
| $67 |
3%
upside
| 2 | +1.6% |
0
%
| 29 Jan ‘26 1 month ago |
|
|
|
Neutral
Maintained
| $130 |
7%
upside
| 1 | – |
–
| 23 Jan ‘26 1 month ago |
|
|
|
Overweight
Reiterated
| $21 |
23%
upside
| 1 | +9.4% |
0
%
| 22 Jan ‘26 1 month ago |
|
|
|
Neutral
Assumed
| $45 |
12%
upside
| 1 | – |
–
| 15 Jan ‘26 1 month ago |
|
|
|
Overweight
Assumed
| $152 |
12%
upside
| 1 | +7.7% |
0
%
| 15 Jan ‘26 1 month ago |
|
|
|
Overweight
Assumed
| $42 |
20%
upside
| 1 | +1% |
0
%
| 17 Dec ‘25 2 months ago |
|
|
|
Neutral
Assumed
| $13 |
3%
upside
| 1 | – |
–
| 17 Dec ‘25 2 months ago |
|
|
|
Overweight
Assumed
| $21 |
18%
upside
| 1 | +4.3% |
0
%
| 17 Dec ‘25 2 months ago |
|